Trial Profile
A Biological Basis of Therapy for Negative Symptom Spectrum Disorders: Risperdal Effect on Frontal Metabolism in Asperger's Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Asperger syndrome
- Focus Biomarker; Therapeutic Use
- 19 Jul 2011 Actual end date (1 Sep 2008) added as reported by ClinicalTrials.gov.
- 19 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Nov 2006 New trial record.